512 results about "Liver adenocarcinoma" patented technology

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with liver cancer. The biological compositions can be used to retard the growth of liver cancer cells and/or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

The invention discloses a meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and a preparation method thereof. Firstly, meso-porous silicon nano-particles are prepared with a sol-gel method, and are developed into a nanometer reservoir of drug molecules; then a disulfide bond is introduced into the surface of the meso-porous silicon nanometer reservoir with a simple chemical modification method and is used as a cohesive tie; secondarily, a biocompatible natural extracellular matrix-collagen molecule is creatively fixed to the surface of the meso-porous silicon nanometer reservoir and is developed into a nanometer encapsulator of the meso-porous silicon nanometer reservoir; and finally a lactobionic acid molecule is modified to the surface of a meso-porous silicon/collagen nanometer compounding system and is used as a specificity receptor of a liver cancer cell membrane surface receptor (ASGP-R) so as to construct a meso-porous silicon/collagen-lactobionic acid multifunctional compound type nano-drug carrier system with both cell specificity targeting ability and reducing substance/enzyme responsiveness.

The invention discloses a class of anti-tumor compounds containing a triazole heterocyclic structure and an application thereof, belonging to the technical field of medicinal chemistry. The compounds containing the triazole heterocyclic structure introduce quintuple 1,2,3-triazole ring in the form of side chains through the amino condensation, bromination, nitrine substitution, link reaction and other reactions on the basis of naphthalimide parent structure, select tetrazolium salt reduction to test 7721 hepatocellular in the experiment of inhibiting proliferation of tumor cells, and also select sulfonyl rhodamine B protein staining method to test MCF-7 breast cancer cells. The experiment results show that the anti-tumor compounds have wide anti-tumor activity and good inhibition effect on the normal growth of tumor cells derived from different tissues of liver cancer, breast cancer and the like.

The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The invention relates to a CRISPR/Cas12a gene editing system and application thereof. The invention comprehensively utilizes biochemical, molecular biology, cell biology and other methods to screen and identify novel LiCas12a protein with endonuclease activity from a plurality of different bacteria. Based on LiCas12a, a CRISPR/LiCas12a gene editing system with high editing efficiency and high specificity is established in eukaryotic cells and prokaryotic cells separately, and genetic manipulation such as knockout, insertion and point mutation of genes is achieved; a molecular mechanism that the mutation of a TERT gene promoter promotes the cell proliferation of bladder cancer and liver cancer is disclosed. The genetic editing system based on CRISPR-LiCas12a provides a more accurate and efficient gene editing method for research fields such as disease pathogenesis and metabolic engineering transformation.

The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.

The invention provides the application of carbon nanotube-chitosan-phycocyanin complex in the preparation of antitumor drugs. The carbon nanotube-chitosan-phycocyanin complex is composed of multi-walled carbon nanotubes, Chitosan and spirulina phycocyanin are formed by non-covalent combination. The complex has good growth inhibitory effect on breast cancer MCF-7 cells and liver cancer HepG2 cells, especially under the irradiation of near-infrared light and visible light. The inhibitory effect was further strengthened, and all showed the characteristics of killing tumor cells. As an anti-tumor biomedical material, the carbon nanotube-chitosan-phycocyanin composite provided by the invention has broad prospects in photodynamic therapy and photothermal therapy of tumor cells.

The invention relates to dibenzo iodonium salts represented by the following structural formula (I), and discloses a preparation method and an application thereof. In in-vitro experiments, the iodonium salts substantially inhibit the growths of cells of human-sourced pancreatic cancer, stomach cancer, colon cancer and other malignant tumors, and provide substantially killing effects against cells of ovarian cancer, lung cancer, liver cancer, leukemia, glioma, bone marrow cancer and other malignant tumors. In animal experiments, with the salts, the growths of human pancreatic cancer and colon cancer xenografts in nude mice can be substantially inhibited. The compounds can be used in developing novel antitumor medicines. (I) is shown below.

The invention discloses a liver-cancer-targeted doxorubicin-supporting silica-gold composite material, and a preparation method and application thereof. The composite material comprises silica-gold nanometer core-shell particles, a targeting adhesion peptide and doxorubicin; doxorubicin is subjected to chemical modification for forming A SH-PEG-Dox prodrug, and the prodrug is linked to silica-gold nanometer core-shell particles via Au-S bonds; and the targeting adhesion peptide is linked to the silica-gold nanometer core-shell particles via Au-S bonds. The material is good in biological compatibility, has specific optical properties and good targeting property, the material can enable the supported medicine to be transferred to liver cancer cells and rapidly releases the medicine, and the material has the cooperative treatment effects of chemotherapy and thermotherapy.

The invention belongs to the technical field of new drug synthesis, in particular to a class of 4-amino-6-(3-(3-bromophenyl)phenyl)-5-cyano-7-(β-L-xylofuranose)pyrrolo [2,3-d]pyrimidine, its similar derivatives, and drugs for preparing anti-human liver cancer cells, human lung cancer cells, human breast cancer cells, human cervical cancer cells, and human gastric cancer cells. The compounds of the present invention are directed against 4-amino-6-(3-(3-bromophenyl)phenyl)-5-cyano-7-(β-L-xylofuranose)pyrrolo[2,3 -d] The C6 position of pyrimidine is modified and synthesized by chemical methods. Experiments have shown that this type of compound can significantly inhibit the proliferation of various cancer cells, effectively induce apoptosis of cancer cells, including highly metastatic cancer cells, and can be used as drugs and drug components for treating cancer.

The invention discloses a compound lithocarolsA-F, a preparation method and application thereof in preparation of antitumor drugs. The compound lithocarolsA-F is isolated from a fermentation culture of marine fungi Phomopsis lithocarpus FS508. Experiments prove that the IC50 values of the compound lithocarolsA-F on liver cancer cells HepG-2, breast cancer cells MCF-7, glioma cells SF-268 and non-small cell lung cancer cells A549 are 10.5-87.7 muM, showing that the compound lithocarolsA-F has relatively significant antitumor activity and can be used for preparing antitumor drugs.

The invention relates to a hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength and a preparation method and an application thereof, and belongs to the field of chemical medicine. The compound is represented as the following formula described in the description. The compound of hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has inhibition effects in different degrees on human liver cancer cell Hep G2 in anticancer activity evaluation in vitro. The ratio of photoactivity to dark activity and the ratio of sono-activity to dark activity are much higher than that of hemoporphyrinmonomethyl ether as a positive contrast. The hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has advantages of low toxicity, high efficiency, treatment wavelength moving towards long wave region and the like. The compound in the invention can be used as an excellent photosensitizer and an excellent sonosensitizer for photodynamic and sonodynamic therapy of tumors.

The invention relates to ursolic acid derivatives with anticancer activity and a preparation method thereof. In the method, a carbonoxyl group at the C-28 position of ursolic acid is connected with natural alpha-amino acid through ethanediamine in a mode of forming an amido bond to synthesize a series of ursolic acid derivatives with anticancer activity. In-vitro pharmacological experiments indicate that the ursolic acid derivatives chemically modified by amino acid have obvious in-vitro inhibition effect on human liver cancer HepG2 cells, human colon cancer HT-29 cells, human gastric cancer AGS and BGC-823cells, and human prostatic cancer PC-3 cells.

The invention belongs to the biological medicine field, in particular relating to the use of a high efficiency small interfering RNA for preparing a tumor migration inhibition drug. The high efficiency small interfering RNA can silence the expression of survivin, change the adhesive force of breast cancer, gastric cancer and liver cancer cells against IV collagen, and inhibit the migrating ability of the breast cancer, gastric cancer and liver cancer cells at two-and three-dimensional levels. The small interfering RNA can also prepare the drug for inhibiting the tumor migration.

The invention relates to a preparation method of hydronopyl triethyl ammonium iodide, and an application of the prepared hydronopyl triethyl ammonium iodide in preparation of an inhibitor for treating tumor. The compound has obvious inhibition effect for tumor cells, and the preparation method of hydronopyl triethyl ammonium iodide is characterized in that hydronopyl chlorine is reacted to sodium iodide to prepare hydronopyl iodine, and the hydronopyl iodine is reacted to triethylamine to obtain hydronopyl triethyl ammonium iodide. The prepared hydronopyl triethyl ammonium iodide has median inhibitory concentration 50 (IC50 ) value of human lung cancer H460 cells, human breast cancer MCF7 cells, human liver cancer SMMC7721 cells, human stomach cancer MK-45 cells as 8.3mum g/ml, 13.25mum g/ml, 2.28mum g/ml and 1.27mum g/ml, which are most basically less than 10 mum g/ml, and partially achieves the requirements of SFDA antitumor drug pharmacodynamics guidance principle, and expresses good antineoplastic activity.

The invention relates to a yellow mushroom standardized component manufacturing method. The method comprises the following steps: (1) drying and crushing yellow mushrooms, then performing water extraction, centrifugally collecting mushroom residues, extracting the mushroom residues with acetone, centrifugally collecting filtrate, and performing reduced pressure concentration on the filtrate to form paste, namely an acetone extract; (2) dissolving the acetone extract in an n-hexane-ethyl acetate mixed solution, then filtering to obtain a sample solution containing the acetone extract, and separating the sample solution containing the acetone extract on a preparation chromatogram to obtain 14 standardized component samples, namely Fr1, Fr2,..., Fr13 and Fr14; and (3) performing anti-liver cancer cell model screening in vitro on the 14 standardized component samples by an iCelligence real-time label-free cell analyzer, thus determining that the 7th, the 8th, the 9th, the 10th, the 11th, the 13th and the 14th standardized component have human liver cancer cell adherence and proliferation inhibition activity in vitro. The yellow mushroom standardized component manufacturing method provided by the invention has the advantages of simple process and easiness in implementation. Simultaneously, the obtained active components can be applied to treatment of liver cancer.

The invention relates to an oroxylum indicum general flavone extraction and purification method. Ethyl alcohol backflow and macroporous resin adsorption are used for separating, extracting and purifying oroxylum indicum general flavone, non-flavonoid impurities are removed as many as possible, and finally enrichment is carried out to obtain the high-purity general flavone. The oroxylum indicum general flavone comprises five chemical components including semen oroxyli glycoside B, semen oroxyli glycoside A, chrysin-7-O-beta-D-glucuronide, baicalein and chrysin. The invention further provides application of the oroxylum indicum general flavone to prepating medicine for treating liver cancers. In-vitro pharmacological tests show that the general flavone has the obvious restraining effect on proliferation of liver cancer cells and trends to have the obvious dose-effect relationship, and meanwhile the pharmacological effect is obviously improved along with increase of the purity of the general flavone; in addition, oroxylum indicum general flavone matter analysis studying is carried out, the material basis of oroxylum indicum for playing a role in anti-cancer pharmacological effect is defined, and the material basis and the experiment basis are laid for developing clinical application of oroxylum indicum general flavone enrichment matter, anti-cancer new medicine researching and development and industrial production.

The invention discloses piperazine-framework-containing glycyrrhetinic acid derivatives, and a preparation method and application thereof. The structure of the synthesized glycyrrhetinic acid derivatives is disclosed in the specification. The glycyrrhetinic acid derivatives have obvious inhibiting actions on human liver cancer cells (HepG2), human mammary cancer cells (MCF-1), cervical cancer cell lines (Hela cells) and human lung adenocarcinoma cells (A549). Therefore, the piperazine-framework-containing glycyrrhetinic acid derivatives can be used for preparing antineoplastic drugs.

The invention discloses pyrazolyl steroid derivatives having a structure shown in the formula (I) in the specification, wherein substituent R1 can be H, nitryl or halogen, substituent R2 can be C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl or monosubstituted or polysubstituted aryl. The synthesis route of the pyrazolyl steroid derivatives takes pregnenolone as a raw material; the method is used for synthesizing the pyrazolyl steroid derivatives for the first time and has the advantages of high yield, easy separation and the like. The pyrazolyl steroid derivatives show inhibitory activity for human lung adenocarcinoma cell, cervical carcinoma cell line and hepatoma carcinoma cell and have a prospect of being developed into anti-cancer drug or medicine compositions.